Exchange: NYSE·Updated 07:30 PM EDT

GKOS News

News
all
press releases
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
Zacks
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
Zacks
More News
$1000 Invested In Glaukos 10 Years Ago Would Be Worth This Much Today
Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 1.4% on an annualized basis producing an average annual return of 14.97%. Currently, Glaukos has a market capitalization of $9.57 billion.read more...
Benzinga
Glaukos Partners with NBA Champion Stephen Curry to Launch Could it be KC? Campaign to Raise Awareness of Keratoconus
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the launch of Could it be KC?, a new disease awareness and educational campaign launching...
Business Wire
Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.
Zacks
Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
Glaukos (NYSE:GKOS) has outperformed the market over the past 5 years by 15.09% on an annualized basis producing an average annual return of 26.17%. Currently, Glaukos has a market capitalization of $10.97 billion.read more...
Benzinga
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.
Zacks
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.
Zacks
Glaukos Announces Participation in Wells Fargo Healthcare Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference...
Business Wire

Advertisement|Remove ads.